ノギテカン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ノギテカン" in Japanese language version.

refsWebsite

Global rank Japanese rank

17nih.gov

4^th place

24^th place

10doi.org

2^nd place

6^th place

2web.archive.org

1^st place

1japic.or.jp

low place

3,742^nd place

1pmda.go.jp

6,690^th place

394^th place

1fda.gov

447^th place

1,043^rd place

1onctalk.com

low place

1drugs.com

399^th place

1,603^rd place

1semanticscholar.org

11^th place

1,537^th place

1archive.org

6^th place

146^th place

1zenodo.org

621^st place

4,635^th place

1harvard.edu

18^th place

107^th place

archive.org

Cordell, Geoffrey, ed (2003). The Alkaloids: Chemistry and Biology. California: Academic Press. pp. 1–50. ISBN 978-0080521497

doi.org

“Mechanism-based models for topotecan-induced neutropenia”. Clinical Pharmacology and Therapeutics 76 (6): 567–78. (December 2004). doi:10.1016/j.clpt.2004.08.008. PMID 15592328.
“Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan”. Journal of Clinical Oncology 22 (14 suppl): 2015. (July 2004). doi:10.1200/jco.2004.22.90140.2015. PMID 28015603.
“Recent developments in the clinical activity of topoisomerase-1 inhibitors”. Update on Cancer Therapeutics 1 (2): 117–145. (2006). doi:10.1016/j.uct.2006.05.010.
“Mutation analysis of UBE3A in Angelman syndrome patients”. American Journal of Human Genetics 62 (6): 1353–60. (June 1998). doi:10.1086/301877. PMC 1377156. PMID 9585605.
“Neurodevelopmental disorders: Unsilencing dormant Ube3a--hope for Angelman syndrome?”. Nature Reviews. Neurology 8 (2): 62. (January 2012). doi:10.1038/nrneurol.2012.2. PMID 22270025.
“Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons”. Nature 481 (7380): 185–9. (December 2011). doi:10.1038/nature10726. PMC 3257422. PMID 22190039.
“DNA topoisomerases and their poisoning by anticancer and antibacterial drugs”. Chemistry & Biology 17 (5): 421–33. (May 2010). doi:10.1016/j.chembiol.2010.04.012. PMC 7316379. PMID 20534341.
“Topoisomerase I inhibitors: camptothecins and beyond”. Nature Reviews. Cancer 6 (10): 789–802. (October 2006). doi:10.1038/nrc1977. PMID 16990856. https://zenodo.org/record/1233494.
“The mechanism of topoisomerase I poisoning by a camptothecin analog”. Proceedings of the National Academy of Sciences of the United States of America 99 (24): 15387–92. (November 2002). Bibcode: 2002PNAS...9915387S. doi:10.1073/pnas.242259599. PMC 137726. PMID 12426403.
“Induction of a common pathway of apoptosis by staurosporine”. Experimental Cell Research 211 (2): 314–21. (April 1994). doi:10.1006/excr.1994.1093. PMID 8143779.

drugs.com

“GSK Receives Approval for Hycamtin (topotecan) Capsules for theTreatment of Relapsed Small Cell Lung Cancer”. 2021年4月22日閲覧。

fda.gov

“FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix”. FDA/Center for Drug Evaluation and Research. 2008年11月7日時点のオリジナルよりアーカイブ。2009年2月7日閲覧。

harvard.edu

ui.adsabs.harvard.edu

“The mechanism of topoisomerase I poisoning by a camptothecin analog”. Proceedings of the National Academy of Sciences of the United States of America 99 (24): 15387–92. (November 2002). Bibcode: 2002PNAS...9915387S. doi:10.1073/pnas.242259599. PMC 137726. PMID 12426403.

japic.or.jp

pins.japic.or.jp

“ハイカムチン注射用1.1mg 添付文書”. 日本医薬情報センター. 2021年4月22日閲覧。

nih.gov

onctalk.com

“Oral Topotecan FDA Approved in US for Second Line SCLC”. Onc Talk. 2009年6月26日時点のオリジナルよりアーカイブ。2009年2月7日閲覧。

pmda.go.jp

info.pmda.go.jp

“ハイカムチン注射用1.1mg インタビューフォーム”. PMDA. 2021年4月22日閲覧。

semanticscholar.org

“Neurodevelopmental disorders: Unsilencing dormant Ube3a--hope for Angelman syndrome?”. Nature Reviews. Neurology 8 (2): 62. (January 2012). doi:10.1038/nrneurol.2012.2. PMID 22270025.

web.archive.org

“FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix”. FDA/Center for Drug Evaluation and Research. 2008年11月7日時点のオリジナルよりアーカイブ。2009年2月7日閲覧。
“Oral Topotecan FDA Approved in US for Second Line SCLC”. Onc Talk. 2009年6月26日時点のオリジナルよりアーカイブ。2009年2月7日閲覧。

zenodo.org

“Topoisomerase I inhibitors: camptothecins and beyond”. Nature Reviews. Cancer 6 (10): 789–802. (October 2006). doi:10.1038/nrc1977. PMID 16990856. https://zenodo.org/record/1233494.